0 11 Angiotensin Angiotensin NNP 12 14 II ii CD 15 24 activates activate VBZ 25 28 the the DT 29 44 proinflammatory proinflammatory JJ 45 58 transcription transcription NN 59 65 factor factor NN 66 73 nuclear nuclear JJ 74 87 factor-kappaB factor-kappab NN 88 90 in in IN 91 96 human human JJ 97 106 monocytes monocyte NNS 106 107 . . . 109 112 The the DT 113 130 renin-angiotensin renin-angiotensin NN 131 137 system system NN 138 141 may may MD 142 152 contribute contribute VB 153 155 to to TO 156 159 the the DT 160 172 pathogenesis pathogenesis NN 173 175 of of IN 176 191 atherosclerosis atherosclerosis NN 191 192 . . . 193 194 A a DT 195 201 common common JJ 202 209 feature feature NN 210 212 of of IN 213 216 all all DT 217 223 stages stage NNS 224 226 of of IN 227 242 atherosclerosis atherosclerosis NN 243 245 is be VBZ 246 258 inflammation inflammation NN 259 261 of of IN 262 265 the the DT 266 272 vessel vessel NN 273 277 wall wall NN 277 278 . . . 279 282 The the DT 283 296 transcription transcription NN 297 303 factor factor NN 304 311 nuclear nuclear JJ 312 325 factor-kappaB factor-kappaB NNP 326 327 ( ( ( 327 336 NF-kappaB NF-kappaB NNP 336 337 ) ) ) 338 350 participates participate VBZ 351 353 in in IN 354 358 most most JJS 359 368 signaling signaling NN 369 377 pathways pathway NNS 378 386 involved involve VBN 387 389 in in IN 390 402 inflammation inflammation NN 402 403 . . . 404 408 This this DT 409 414 study study NN 415 424 therefore therefore RB 425 433 examined examine VBD 434 437 the the DT 438 444 effect effect NN 445 447 of of IN 448 459 angiotensin angiotensin NN 460 461 ( ( ( 461 464 ANG ANG NNP 464 465 ) ) ) 466 468 II ii CD 469 471 on on IN 472 481 NF-kappaB NF-kappaB NNP 482 492 activation activation NN 493 495 in in IN 496 505 monocytic monocytic JJ 506 511 cells cell NNS 511 512 , , , 513 514 a a DT 515 520 major major JJ 521 529 cellular cellular JJ 530 539 component component NN 540 542 of of IN 543 548 human human JJ 549 557 atheroma atheroma NN 557 558 , , , 559 561 by by IN 562 577 electrophoretic electrophoretic JJ 578 586 mobility mobility NN 587 592 shift shift NN 593 598 assay assay NN 598 599 . . . 600 603 ANG ANG NNP 604 606 II ii CD 606 607 , , , 608 612 like like IN 613 621 TNFalpha TNFalpha NNP 621 622 , , , 623 629 caused cause VBD 630 635 rapid rapid JJ 636 646 activation activation NN 647 649 of of IN 650 659 NF-kappaB NF-kappaB NNP 660 662 in in IN 663 668 human human JJ 669 680 mononuclear mononuclear JJ 681 686 cells cell NNS 687 695 isolated isolate VBN 696 700 from from IN 701 711 peripheral peripheral JJ 712 717 blood blood NN 718 720 by by IN 721 727 Ficoll Ficoll NNP 728 735 density density NN 736 744 gradient gradient NN 744 745 . . . 746 750 This this DT 751 754 ANG ANG NNP 755 757 II ii CD 758 764 effect effect NN 765 768 was be VBD 769 776 blocked block VBN 777 779 by by IN 780 783 the the DT 784 795 angiotensin angiotensin NN 796 799 AT1 at1 NN 800 808 receptor receptor NN 809 819 antagonist antagonist NN 820 828 losartan losartan NN 828 829 . . . 830 841 Specificity specificity NN 842 844 of of IN 845 848 ANG ANG NNP 849 859 II-induced ii-induced JJ 860 869 NF-kappaB NF-kappaB NNP 870 880 activation activation NN 881 884 was be VBD 885 896 ascertained ascertain VBN 897 899 by by IN 900 910 supershift supershift NN 911 914 and and CC 915 926 competition competition NN 927 938 experiments experiment NNS 938 939 . . . 940 948 Moreover moreover RB 948 949 , , , 950 953 ANG ANG NNP 954 956 II ii CD 957 967 stimulated stimulate VBD 968 977 NF-kappaB NF-kappaB NNP 978 988 activation activation NN 989 991 in in IN 992 997 human human JJ 998 1007 monocytes monocyte NNS 1007 1008 , , , 1009 1012 but but CC 1013 1016 not not RB 1017 1019 in in IN 1020 1031 lymphocytes lymphocyte NNS 1032 1036 from from IN 1037 1040 the the DT 1041 1045 same same JJ 1046 1057 preparation preparation NN 1057 1058 . . . 1059 1067 Together together RB 1067 1068 , , , 1069 1072 the the DT 1073 1077 data datum NNS 1078 1089 demonstrate demonstrate VBP 1090 1093 the the DT 1094 1101 ability ability NN 1102 1104 of of IN 1105 1108 the the DT 1109 1119 vasoactive vasoactive JJ 1120 1127 peptide peptide NN 1128 1131 ANG ANG NNP 1132 1134 II ii CD 1135 1137 to to TO 1138 1146 activate activate VB 1147 1159 inflammatory inflammatory JJ 1160 1168 pathways pathway NNS 1169 1171 in in IN 1172 1177 human human JJ 1178 1187 monocytes monocyte NNS 1187 1188 . . . 1189 1198 Copyright Copyright NNP 1199 1203 1999 1999 CD 1204 1212 Academic Academic NNP 1213 1218 Press Press NNP 1218 1219 . . .